PREDICTOM

About PREDICTOM

Alzheimer’s disease (AD) and related disorders leading to dementia are associated with staggering costs and suffering. In 2023, more than 7 million people are living with dementia in the European Union. This number is projected to double, reaching 14 million in 2050. This will create a huge burden on healthcare systems.

Recently, there has been some progress in the search for effective therapeutic interventions and it is clear that any treatment is likely to be most effective if administered at the earliest stage of disease. Therefore there is an urgent need to establish scalable, cost-efficient diagnostic markers, tools and procedures that can identify people at increased risk to prevent or delay dementia. 

PREDICTOM will develop an open-source, interoperable and customisable biomarker screening platform. This platform will bring diagnostics closer to the patient by examining the feasibility of using samples which can be obtained at home or GP offices (e.g. finger-prick blood, saliva, stool, digital markers) for diagnostic biomarker analysis. The platform will use artificial intelligence models to analyse data from all biomarkers to identify users at high risk of developing dementia to prevent further cognitive decline and development of dementia. PREDICTOM seeks to facilitate a change in current healthcare practice for early diagnosis of AD through development of new clinical practice guidelines. By improving the ease of identification of those with early signs of dementia the project expects to have a significant impact on personal and financial burden of dementia in Europe and across the world.

Lygature in PREDICTOM

In PREDICTOM Lygature is leading the program management work package together with co-lead GE HealthCare GmbH. Responsibilities include ensuring the proper overall management of the project to support the participants in achieving objectives and completing milestones and deliverables according to the defined timeframes. This includes stimulating transparency, driving collaboration between partners, the compilation of periodic technical reports, and monitoring the effective execution of the work plan and its progress. In addition, Lygature provides to the consortium its specifically developed IT platform, which includes a publication approval system to safeguard scientific confidentiality and enable smooth dissemination of consortium results.

Lygature together with

Acknowledgement of support

PREDICTOM is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101132356. The JU receives support from the European Union’s Horizon Europe research and innovation programme and  Helse Stavanger HF, Kings College London, Foundation Lygature, Ethnniko Kentro Erevnas kai Technolgikis Anaptyxis - Centre for Research and Technology Hellas, Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., JOANNEUM RESEARCH Forschungsgesellschaft mbH., Qairnel SAS, Ludwig-Maximilians-Universitaet Muenchen, National Institute for Health and Care Excellence, Alzheimer Europe, Pharmacoidea Fejleszto es Szolgaltato KFT, Novo Nordisk A/S, GE HealthCare GmbH, Siemens Healthineers AG, The University of Exeter, Icometrix nv, Universitatsklinikum Erlangen, Vrije Universiteit Brussel, Fundacion Para la Investigacion del Hospital Universitario La Fe de la Comunidad Valenciana, ALZpath Inc, GN Hearing AS, Muhdo Health Ltd, Université de Genève, Altoida Inc, and BrainCheck Inc. 

Disclaimer

Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.